Mission Pet Health vs NVA vs Mars: The 2026 Buyer Comparison Guide

Key takeaways

• Mission Pet Health, NVA, and Mars are the three largest buyer categories in US veterinary practice M&A in 2026, but they differ fundamentally in ownership, exit timeline, and how they approach a deal.
• Mission Pet Health is the newest of the three — the unified brand launched in July 2025 after the December 2024 merger of Southern Veterinary Partners and Mission Veterinary Partners, backed by Shore Capital and Silver Lake. It now operates 850-plus hospitals across 41 states.
• NVA is a JAB Holdings platform with approximately 1,400 general practice locations, tracking toward an eventual IPO, and operates one of the largest locally-branded GP networks in the world.
• Mars Veterinary Health is the only strategic buyer of the three — family-owned, no PE exit cycle, and the largest single owner of veterinary hospitals in the US with more than 2,300 clinics across VCA, Banfield, and BluePearl.
• The right buyer for your practice depends on your goals, timeline, and deal structure preferences — and is almost never obvious from a direct conversation with one buyer’s acquisition team. A competitive process reveals what each buyer will actually pay.

The question comes up in almost every seller conversation I’m in these days. An owner has received outreach — sometimes from all three at once — and they want to understand what they’re actually looking at before they pick up the phone.

Mission Pet Health vs NVA vs Mars. Three names, three very different institutions, and a lot of noise about which one is “best.”

I tell them the same thing. Understanding the buyers is the foundation, but it doesn’t answer the decision.

The decision answers itself once you see what each buyer actually puts on paper when they know there’s real competition for your practice.

What I can do first is help you see these three platforms clearly — their ownership, their scale, what they’re trying to accomplish, and how they approach a practice acquisition. That’s this article.

After that, we get into what actually determines which one is right for you, and why the answer is almost never a direct offer from any of them in isolation.

The short version, for anyone who wants to skim before reading: Mission Pet Health vs NVA vs Mars is a comparison of a newly unified PE-backed consolidator, a globally scaled PE-backed GP network on an IPO track, and the strategic family-owned exception that owns more US veterinary hospitals than anyone else. All three are serious, well-capitalized buyers for the right practice.

None of them publishes a standard price sheet, and none of them shows you their best offer unless they have a reason to.

What is Mission Pet Health vs NVA vs Mars — the quick version for 2026?

Mission Pet Health, NVA, and Mars are the 3 largest institutional buyers active in US general-practice veterinary M&A in 2026. They differ in ownership and exit structure. Mission Pet Health is PE-backed, formed from the December 2024 merger of Southern Veterinary Partners and Mission Veterinary Partners, with Shore Capital and Silver Lake as co-sponsors. NVA is PE-backed under JAB Holding Company, the largest GP-focused vet network in the world by location count. Mars is the strategic exception — family-owned, no PE exit cycle, operating VCA, Banfield, and BluePearl.

All 3 actively acquire general practices above approximately $2 million in revenue.

Who is Mission Pet Health and where did it come from?

The platform that practice owners now see approaching them as “Mission Pet Health” is one of the most significant structural changes in veterinary consolidation in recent years. It deserves context before we get to the deal side.

Southern Veterinary Partners (SVP) and Mission Veterinary Partners (MVP) were both Shore Capital Partners platforms — two of the most active acquirers in the US general-practice market. SVP had built a network of 420-plus practices.

MVP had assembled another 330-plus. Shore had been backing both on parallel tracks, and by mid-2024, the decision was made to merge them.

The merger formally closed in December 2024. Shore Capital brought in Silver Lake — a Menlo Park-based technology and growth-oriented private equity firm — as a co-investor in an approximately $8.6 billion recapitalization that financed the combination.

The two PE firms together contributed approximately $4 billion in fresh equity, with the balance structured as secured debt and preferred equity.

The unified brand, Mission Pet Health, launched publicly in July 2025. As of that launch, the combined platform operates 850-plus hospitals across 41 US states, per Mission Pet Health’s own press release from July 21, 2025.

For sellers, the practical meaning of the merger is this: if you received an outreach from SVP or MVP over the past two to three years, those conversations now live under the Mission Pet Health umbrella. The acquisition team is unified.

The deal template has largely standardized around SVP’s partnership-model approach. And the platform’s scale now makes it one of the largest potential bidders in any competitive process involving a US general practice.

Mission Pet Health describes its acquisition model as a partnership model — a deal structure in which the consolidator acquires a majority stake while the selling veterinarian retains a defined equity interest, subject to a put/call buyout at a future date. The timing of the retained-equity buyout in standard partnership structures is commonly around year five, though terms vary by deal. The seller does not receive all-cash at close. Total proceeds arrive across two stages: the majority payment at closing and the retained-equity buyout later. That structure has meaningful implications for how you compare a Mission Pet Health offer to an all-cash offer from NVA, Mars, or an independent buyer.

Who is NVA and what does it look like in 2026?

NVA — National Veterinary Associates — is one of the longest-standing institutional buyers in the US veterinary market. It has been building through acquisition since the early 2000s, and it’s the organization that set much of the playbook the subsequent wave of PE-backed consolidators followed.

JAB Holding Company — a Luxembourg-based privately held investment group with holdings across consumer brands including Krispy Kreme and Peet’s Coffee — acquired NVA in 2019. JAB’s investment philosophy is oriented toward long-term consumer brands, which has shaped NVA’s operating approach.

NVA describes itself as focused on locally branded practices: the hospital keeps its name, its team, and its community identity under NVA ownership. That positioning is worth noting in the context of how practice sellers think about post-sale identity.

Since the JAB acquisition, NVA’s GP network has grown to approximately 1,400 locations in the US, Canada, Australia, and New Zealand, according to NVA’s own materials. That number reflects general practice hospitals, equine hospitals, and pet resorts — the GP segment is the dominant piece.

One structural note worth understanding: in March 2023, JAB announced that NVA would separate its specialty and emergency hospitals into a distinct entity called Ethos Veterinary Health. Ethos took on approximately 145 specialty and emergency hospitals — including legacy Ethos, Compassion-First Pet Hospitals, Sage Veterinary Centers, and the NVA specialty hospitals.

That separation was completed, and NVA’s general-practice business now operates independently of Ethos. The two are preparing for eventual public offerings; NVA has been building out public-company leadership accordingly.

For general-practice owners, this means the NVA you’re likely talking to today is specifically the GP platform, not the specialty unit. The split was designed to give each business a focused strategy and a clean IPO path — which shapes NVA’s operational priorities as it moves toward that milestone.

NVA is, by revenue, an approximately $4 billion business according to public commentary at the time of the Ethos separation.

Who is Mars Veterinary Health and why is it different?

Mars Veterinary Health is the structural outlier in this comparison, and understanding why it’s different matters as much as knowing what it is.

Mars is not a private equity firm. It is not PE-backed. Mars, Incorporated is a privately held, family-owned company — the same company that makes M&Ms and Snickers — with a history stretching back more than a century.

That ownership structure means no PE fund cycle, no defined investment horizon, and no LP-driven pressure to exit positions within a set number of years. Mars acquires practices as a permanent strategic owner, not as a financial sponsor seeking a future liquidity event.

Mars operates its US veterinary hospitals under 3 brands:

• VCA Animal Hospitals — acquired by Mars in 2017 for approximately $9.1 billion; 1,000-plus hospitals across 45 US states
• Banfield Pet Hospital — the longest-standing Mars vet brand, with 1,000-plus US locations, most inside PetSmart stores
• BluePearl Pet Hospital — Mars’s specialty and emergency brand, with 100-plus US hospitals

Combined, Mars Veterinary Health operates more than 2,300 US clinics, making it the single largest owner of veterinary hospitals in the country by location count, per Mars’s own published materials. Mars also operates AniCura and Linnaeus in Europe, bringing the global hospital count to nearly 3,000.

The strategic buyer distinction has a practical meaning for practice sellers: a Mars conversation, specifically via VCA, carries a different post-sale framework than a PE-backed conversation. VCA hospitals have historically retained their local names and operated as VCA-branded practices after acquisition — the VCA umbrella operates at the network level, not by rebranding individual hospitals.

But the ownership structure is permanent, not a 5-to-7-year hold. A seller considering a VCA or Mars conversation should understand they are aligning with a long-term strategic owner, not a PE sponsor planning to exit.

How do the three compare? A side-by-side view

	Mission Pet Health	NVA	Mars Veterinary Health (VCA)
Ownership type	PE-backed	PE-backed	Strategic (family-owned)
PE sponsor(s)	Shore Capital + Silver Lake	JAB Holding Company	None — Mars, Inc. family
Exit timeline	PE fund cycle	Planning toward IPO	Permanent owner — no exit
US hospital count	850-plus (41 states)	~1,400 GP locations	2,300-plus (VCA + Banfield + BluePearl)
Key GP brand	Mission Pet Health	NVA General Practice	VCA Animal Hospitals
Brand handling	Local identity preserved	Locally branded GP model	VCA brand at network level
Acquisition model	Partnership model (retained equity)	Varies by deal	Asset purchase, varies by deal
Specialty hospitals	Not the primary focus	Ethos Veterinary Health (separate)	BluePearl (specialty)

The table summarizes the structural facts. What it doesn’t capture is the thing that actually moves your outcome: what each buyer puts on paper when there is real competition for your practice.

What Mission Pet Health vs NVA vs Mars means for a seller in 2026

Here’s where I want to shift the conversation, because the buyer comparison is useful context but it’s not the decision.

I’ve watched practice owners spend months researching which of these three is “better” — reading everything they can find, talking to colleagues who sold to one or the other, trying to determine in advance which buyer will offer them more. That research has real value.

Understanding who these buyers are, what they own, and how they operate is the foundation. But the comparison by itself doesn’t tell you what any of them will offer your practice, on your timeline, with your specific profile.

What tells you that is a competitive process.

EBITDA — what your practice earns in pure operating profit, before taxes and accounting choices — is the starting point every buyer uses to set a price. The multiple — the multiplier applied to that EBITDA number to arrive at a price — is where the competitive process does its work. Two buyers looking at the same practice, with the same EBITDA, will sharpen very different numbers when they know there are other qualified buyers at the table versus when they believe they’re the only conversation.

Capstone Partners‘ April 2026 Pet Sector M&A Update noted 18 announced or completed vet-segment transactions in year-to-date 2026 compared with 8 in the prior year period, and described financial sponsor activity strengthening through 2026 and 2027. Octus’s analysis of private credit exposure to veterinary rollups found that as of the third quarter of 2025, BDCs held $3.1 billion in principal lent to veterinarian companies — a measure of how deeply capitalized the buyer pool is.

These are well-funded institutions with real acquisition appetites. That appetite is what you want competing on your behalf.

The gap between a single direct offer and the outcome of a structured competitive process consistently runs into real money. Across the deals we’ve closed over the past four-plus years, almost all of that gap lands in the multiple — and nearly every major buyer type has participated as a bidder in those processes.

Which buyer is right for your practice?

The honest answer is: it depends on your practice’s profile, your timeline, and what post-sale structure works for your life. Let me give you the dimensions that actually matter.

Partnership model vs all-cash. Mission Pet Health’s standard template involves the seller retaining equity and receiving proceeds in two stages — at closing and at the future buyout of the retained stake. That’s meaningfully different from an all-cash sale.

If you want the cleanest possible exit with full liquidity at close, the structure matters as much as the headline number. If you’re open to retaining an equity stake — which can be a compelling bet if the platform performs — the partnership model merits serious consideration.

Neither is right or wrong. They’re different instruments, and they suit different sellers.

PE-backed vs strategic. A Mars conversation via VCA carries a different long-term dynamic than a Mission Pet Health or NVA conversation. PE-backed buyers are building toward an exit, which creates a certain operating tempo and a specific set of seller incentives — particularly if you’re retaining equity.

A strategic buyer like Mars has a different time horizon. That distinction matters most if you’re planning to stay affiliated with the buyer for several years after closing.

Scale fit. All three platforms actively pursue multi-doctor practices at meaningful revenue levels. But each also has geographic footprint patterns and platform priorities that can affect how aggressively they compete for any specific practice.

A competitive process surfaces which buyers actually want your practice enough to sharpen their offer.

We go deeper on the buyer-selection decision in our guide to who to sell your veterinary practice to. If you’re trying to understand the full competitive landscape beyond these three — including the broader pool of veterinary practice consolidators — that’s the next read after this one.

Why a single conversation with any buyer is almost never your best outcome

I want to be direct about something, because I see owners make this mistake regularly. A direct outreach from Mission Pet Health, NVA, or Mars is not an offer — it’s the beginning of a conversation that will end with that buyer’s assessment of what the practice is worth to them, based on the leverage they perceive in the room.

That assessment goes up when they know other qualified buyers are looking. It stays flat or compresses when they believe they’re the only conversation.

The structure we use is the Elite Selling System — we hand-select and vet every buyer who gets to bid on your practice, the way a doorman with a velvet rope lets in only the right people, then run a private competitive window inside that vetted group. The process has included all three buyer types covered in this article, and many others besides.

The leverage it creates is what drives the multiple, and the multiple is what determines how much of your life’s work you actually keep.

This isn’t about choosing Mission Pet Health vs NVA vs Mars. It’s about making sure that whichever of them is the best fit for your practice is competing hard enough to show you that.

We cover the economics of deal structure in detail — including how earnouts and rollover equity work alongside the headline number — in our pieces on earnout and rollover equity in veterinary practice sales and how much private equity is paying for veterinary practices. And if you’re thinking about the process timeline from start to close, the how long it takes to sell a veterinary practice guide maps that out in full.

What to do next

If you’re getting outreach from Mission Pet Health, NVA, Mars, or any combination of them, the most useful first step isn’t researching the buyer. It’s understanding what your practice is actually worth and which buyer types your profile fits best.

We pull that together as part of a free, no-obligation valuation estimate. We build a defensible normalized EBITDA figure, review how your practice profile compares to what the active buyer pool is pursuing in 2026, and give you a clear picture of what a competitive process might look like before you make any commitment.

Get a Free Practice Value Estimate →

The Transitions Elite engagement model is success-based — no upfront fees, no retainer. We get paid only when a deal closes, and only out of the value our process delivers above what you’d have realized in a direct conversation.

If you’re talking to any of these buyers right now and want a second read on what you’re looking at, that’s exactly the kind of call we’re built for.

---

Frequently asked questions

What is the difference between Mission Pet Health, NVA, and Mars as veterinary practice buyers in 2026?

Mission Pet Health is the PE-backed consolidator formed by the December 2024 merger of Southern Veterinary Partners and Mission Veterinary Partners, backed by Shore Capital and Silver Lake, operating 850-plus hospitals. NVA is a JAB Holdings-backed general-practice consolidator with approximately 1,400 US locations and a planned IPO track.

Mars Veterinary Health is the strategic exception — family-owned by Mars, Inc., operating more than 2,300 US clinics under VCA, Banfield, and BluePearl, with no PE exit cycle. The three differ most in ownership structure, exit timeline, and how each approaches branding and practice integration.

Who is Mission Pet Health and who owns them in 2026?

Mission Pet Health is the unified platform formed when Southern Veterinary Partners and Mission Veterinary Partners completed their merger in December 2024. Shore Capital Partners is the original PE sponsor.

Silver Lake, a large technology and growth-oriented PE firm, co-invested in an approximately $8.6 billion recapitalization that financed the merger. The combined brand launched publicly in July 2025.

Mission Pet Health operates 850-plus hospitals across 41 US states.

Who owns NVA in 2026?

NVA is owned by JAB Holding Company, a Luxembourg-based privately held investment group. JAB acquired NVA in 2019.

Under JAB ownership, NVA has grown significantly and in 2023 separated its specialty and emergency hospitals into a distinct entity called Ethos Veterinary Health. NVA general practice now operates approximately 1,400 locations and has been building toward an eventual IPO.

Is Mars Veterinary Health a private equity buyer?

No. Mars Veterinary Health is owned by Mars, Incorporated, a privately held, family-owned company — not a private equity firm.

Mars has no PE-style exit cycle and no fund-return deadline. VCA, Banfield, and BluePearl all operate under the Mars umbrella.

This makes Mars the strategic buyer exception in the US veterinary consolidation market, structurally different from PE-backed platforms like NVA and Mission Pet Health.

How does Mission Pet Health acquire veterinary practices?

Mission Pet Health uses a partnership-model acquisition approach as its standard template. In a partnership model, the consolidator acquires a majority stake in the practice while the selling veterinarian retains a defined equity interest, typically subject to a put/call buyout at a future date, often around year five.

The structure means the seller does not take all-cash at closing — total proceeds arrive in stages. Mission Pet Health states it offers flexible deal structures across a wide range of options.

How big is NVA compared to Mission Pet Health and Mars in 2026?

Mars Veterinary Health is the largest by US hospital count, operating more than 2,300 US clinics across VCA, Banfield, and BluePearl. NVA operates approximately 1,400 locations in general practice, equine, and pet resort categories across the US, Canada, Australia, and New Zealand.

Mission Pet Health operates 850-plus hospitals in 41 US states. All three are among the handful of buyers that routinely compete for multi-doctor general practices above $2 million in revenue.

Should I sell my veterinary practice to Mission Pet Health, NVA, or Mars?

No single buyer is right for every practice. Each brings different deal structures, timelines, and post-sale operating models.

Mission Pet Health typically brings a partnership structure with retained equity. NVA operates a locally branded GP model and is on a long-term hold.

Mars is a permanent strategic owner under a family-held company. The outcome that best fits your goals — for your practice, your team, and your timeline — depends on the full competitive picture, not on a single buyer’s direct offer.

Running a structured competitive process reveals which buyer actually values your practice most, and under what terms.

What is the difference between a PE-backed buyer and a strategic buyer in veterinary M&A?

A PE-backed buyer, such as NVA or Mission Pet Health, is funded by a private equity firm with a defined investment horizon, typically five to ten years, after which the PE sponsor seeks to exit via a sale or IPO. A strategic buyer, such as Mars Veterinary Health, is a company that acquires practices as a long-term operating business rather than a financial investment with an exit timeline.

The distinction matters because it shapes deal structure, post-sale integration approach, and the buyer’s appetite to pay a premium.

---

More on Selling to Mission Pet Health

• Selling your practice to Mission Pet Health
• Partnership and rollover equity
• Offer and deal structure
• How to evaluate a Mission Pet Health offer

Sources

Industry M&A research and valuation data

1. Capstone Partners. “Pet Sector M&A Update — April 2026.” capstonepartners.com
2. Octus. “Private-Credit Exposure to Veterinary Rollups Shows Growing Dispersion; VSOs Under Increasing Pressure.” 2025. octus.com

Mission Pet Health corporate disclosures and press releases

3. Mission Pet Health. “Southern Veterinary Partners and Mission Veterinary Partners Join Together as Mission Pet Health.” July 21, 2025. missionpethealth.com
4. Mission Pet Health. “Partnerships.” missionpethealth.com
5. Shore Capital Partners. “Mission Pet Health.” Portfolio company page. shorecp.com
6. The Middle Market. “Shore Capital, Silver Lake Reportedly in Talks Over $8.6B Pet Care Deal.” themiddlemarket.com
7. GlobeNewswire. “Southern Veterinary Partners and Mission Veterinary Partners Join Together as Mission Pet Health.” July 21, 2025. globenewswire.com

NVA and JAB Holdings disclosures

8. American Veterinary Medical Association. “NVA splits into two businesses, may go public in next few years.” avma.org
9. BusinessWire. “NVA, the Leading Global Pet Healthcare Organization, to Form Two Distinct Veterinary Businesses.” March 2023. businesswire.com
10. NVA. “Home.” NVA General Practice official site. gp.nva.com

Mars Veterinary Health company disclosures

11. Mars, Incorporated. “Mars, Incorporated to Acquire VCA Inc.” Press release. mars.com
12. Mars Veterinary Health. “Our Companies.” marsveterinary.com
13. Mars Veterinary Health. “Mars Veterinary Health Publishes Inaugural Environmental Sustainability Update.” January 2025. marsveterinary.com